A Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide Combination Maintenance Therapy for Frontline Multiple Myeloma Patients
Sponsor: Takeda
Protocol Number: X16108
Start Date: 12/14/2018
End Date: Closed to Enrollment, projected trial end date 11/2023